Update on dasitinib from DASISION and SPIRIT2 trials for CML

Mhairi Copland, MD, from the University of Glasgow, Glasgow, UK, gives an overview of a session on the long-term outcomes of patients with chronic myeloid leukemia (CML) and dasatinib held at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH) in Glasgow, Scotland. The session provided an update on the efficacy and toxcity of dasitinib based on DASISION (NCT00481247) and SPIRIT2 (NCT01460693). While both trials showed a superiorty for dasitinib in terms of depth of molecular response, this did not translate into improved overall survival (OS) at the two year time point in SPIRIT2 and five year time point in DASISION. In terms of toxicity, the session focused on pleural effusion. According to Prof Copland, physicians and patients should be aware of pleural effusions as it can develop after several years.

Share this video